Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2015 March;67(1) > Minerva Urologica e Nefrologica 2015 March;67(1):65-73

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA UROLOGICA E NEFROLOGICA

Rivista di Nefrologia e Urologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

REVIEW  


Minerva Urologica e Nefrologica 2015 March;67(1):65-73

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Muscle invasive bladder cancer: closing the gap between practice and evidence

Tsao C.-K., Liaw B. C., Oh W. K., Galsky M. D.

Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA


PDF  


Bladder cancer is the fourth most common cancer in the United States, and will lead to an estimated 15,580 deaths in 2014. Prompted by physical symptoms and signs, most patients will initially present with clinically localized disease. Once bladder cancer invades beyond the muscularis propria, the likelihood of development of metastatic disease increases substantially. Radical cystectomy is potentially curative for muscle-invasive bladder cancer though approximately 50% of patients will develop metastatic recurrence. Two large randomized studies have demonstrated that the use of neoadjuvant cisplatin-based chemotherapy prior to cystectomy improves survival. However, despite the existing level 1 evidence, this approach has been largely underutilized in practice. In this review, we will focus on this disconnect between efficacy and effectiveness and explore possible solutions in an effort to bridge this existing gap.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

matthew.galsky@mssm.edu